Anti-HIV activity and resistance profile of the CXC chemokine receptor 4 antagonist POL3026
- PMID: 18182480
- DOI: 10.1124/mol.107.042911
Anti-HIV activity and resistance profile of the CXC chemokine receptor 4 antagonist POL3026
Abstract
We have studied the mechanism of action of Arg(*)-Arg-Nal(2)-Cys(1x)-Tyr-Gln-Lys-(d-Pro)-Pro-Tyr-Arg-Cit-Cys(1x)-Arg-Gly-(d-Pro)(*) (POL3026), a novel specific beta-hairpin mimetic CXC chemokine receptor (CXCR)4 antagonist. POL3026 specifically blocked the binding of anti-CXCR4 monoclonal antibody 12G5 and the intracellular Ca(2+) signal induced by CXC chemokine ligand 12. POL3026 consistently blocked the replication of human immunodeficiency virus (HIV), including a wide panel of X4 and dualtropic strains and subtypes in several culture models, with 50% effective concentrations (EC(50)) at the subnanomolar range, making POL3026 the most potent CXCR4 antagonist described to date. However, 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane (AMD3100)-resistant and stromal cell-derived factor-1alpha-resistant HIV-1 strains were cross-resistant to POL3026. Time of addition experiments and a multiparametric evaluation of HIV envelope function in the presence of test compounds confirmed the activity of POL3026 at an early step of virus replication: interaction with the coreceptor. Generation of HIV-1 resistance to POL3026 led to the selection of viruses 12- and 25-fold less sensitive and with mutations in gp120, including the V3 loop region. However, POL3026 prevented the emergence of CXCR4-using variants from an R5 HIV-1 strain that may occur in the presence of anti-HIV agents targeting CC chemokine receptor 5.
Similar articles
-
Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.J Virol. 2004 Dec;78(23):12996-3006. doi: 10.1128/JVI.78.23.12996-13006.2004. J Virol. 2004. PMID: 15542651 Free PMC article.
-
Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4.J Exp Med. 1997 Oct 20;186(8):1383-8. doi: 10.1084/jem.186.8.1383. J Exp Med. 1997. PMID: 9334378 Free PMC article.
-
AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor.Biochem Pharmacol. 2005 Sep 1;70(5):752-61. doi: 10.1016/j.bcp.2005.05.035. Biochem Pharmacol. 2005. PMID: 16011832
-
HIV co-receptors as targets for antiviral therapy.Curr Top Med Chem. 2004;4(9):883-93. doi: 10.2174/1568026043388501. Curr Top Med Chem. 2004. PMID: 15134547 Review.
-
Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists.Mol Pharmacol. 2000 May;57(5):833-9. Mol Pharmacol. 2000. PMID: 10779364 Review.
Cited by
-
Microtiter plate-based antibody-competition assay to determine binding affinities and plasma/blood stability of CXCR4 ligands.Sci Rep. 2020 Sep 29;10(1):16036. doi: 10.1038/s41598-020-73012-4. Sci Rep. 2020. PMID: 32994431 Free PMC article.
-
Novel targets for antiretroviral therapy: clinical progress to date.Drugs. 2009;69(1):31-50. doi: 10.2165/00003495-200969010-00003. Drugs. 2009. PMID: 19192935 Review.
-
Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4.Leukemia. 2012 Jan;26(1):34-53. doi: 10.1038/leu.2011.197. Epub 2011 Sep 2. Leukemia. 2012. PMID: 21886173 Free PMC article. Review.
-
Antiretroviral agents effectively block HIV replication after cell-to-cell transfer.J Virol. 2012 Aug;86(16):8773-80. doi: 10.1128/JVI.01044-12. Epub 2012 Jun 13. J Virol. 2012. PMID: 22696642 Free PMC article.
-
Peptidomimetics as a new generation of antimicrobial agents: current progress.Infect Drug Resist. 2014 Aug 30;7:229-37. doi: 10.2147/IDR.S49229. eCollection 2014. Infect Drug Resist. 2014. PMID: 25210467 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
